[go: up one dir, main page]

ZA811384B - Labeled antibodies and antibody fragments specific to tumor-associated markers, compositions thereof and use thereof in tumor localization an therapy - Google Patents

Labeled antibodies and antibody fragments specific to tumor-associated markers, compositions thereof and use thereof in tumor localization an therapy

Info

Publication number
ZA811384B
ZA811384B ZA00811384A ZA811384A ZA811384B ZA 811384 B ZA811384 B ZA 811384B ZA 00811384 A ZA00811384 A ZA 00811384A ZA 811384 A ZA811384 A ZA 811384A ZA 811384 B ZA811384 B ZA 811384B
Authority
ZA
South Africa
Prior art keywords
tumor
therapy
compositions
antibody fragments
labeled antibodies
Prior art date
Application number
ZA00811384A
Inventor
M Goldenberg
Original Assignee
M Goldenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M Goldenberg filed Critical M Goldenberg
Publication of ZA811384B publication Critical patent/ZA811384B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA00811384A 1980-03-03 1981-03-03 Labeled antibodies and antibody fragments specific to tumor-associated markers, compositions thereof and use thereof in tumor localization an therapy ZA811384B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/126,262 US4348376A (en) 1980-03-03 1980-03-03 Tumor localization and therapy with labeled anti-CEA antibody

Publications (1)

Publication Number Publication Date
ZA811384B true ZA811384B (en) 1982-11-24

Family

ID=22423880

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA00811384A ZA811384B (en) 1980-03-03 1981-03-03 Labeled antibodies and antibody fragments specific to tumor-associated markers, compositions thereof and use thereof in tumor localization an therapy

Country Status (2)

Country Link
US (1) US4348376A (en)
ZA (1) ZA811384B (en)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311688A (en) * 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4863853A (en) * 1982-04-21 1989-09-05 Bartos Patent Development And Holding Company Limited Method of determining the diagnostic value of monitoring serum-CEA-levels in a carcinoma patient undergoing therapy
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
JPH0811075B2 (en) * 1982-06-30 1996-02-07 雄治 松岡 Monoclonal anti-CEA antibody
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
WO1984002983A1 (en) * 1983-01-21 1984-08-02 Frederick James Primus Specific cea-family antigens, antibodies specific thereto and their methods of use
US4818709A (en) * 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
EP0149709B2 (en) * 1983-07-29 1995-11-29 Milton David Goldenberg Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
IT1174800B (en) * 1983-11-21 1987-07-01 Alberto Bartorelli METHOD FOR THE DETERMINATION OF HUMAN IMMUNOGLOBULINS SPECIFIC FOR HUMAN CARCINOMA ANTIGENS AND ITS USE IN THE SERIOUS DIAGNOSIS OF PRIMITIVE TUMOR FORMS
US4671256A (en) * 1984-05-25 1987-06-09 Lemelson Jerome H Medical scanning, monitoring and treatment system and method
US4674480A (en) * 1984-05-25 1987-06-23 Lemelson Jerome H Drug compositions and methods of applying same
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4775638A (en) * 1985-05-08 1988-10-04 Centocor, Inc. Single vial technique for radiolabeling protein
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4690130A (en) * 1985-12-19 1987-09-01 Mirell Stuart G Electromagnetic therapy control system
US5242823A (en) * 1986-03-07 1993-09-07 International Genetic Engineering, Inc. Cloning of the 38kd Mycoplasma hyorhinis regression-associated antigen
US4902495A (en) * 1986-07-22 1990-02-20 The United States Of America As Represented By The Department Of Health And Human Services IgE Fc directed delivery system
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4939083A (en) * 1986-10-30 1990-07-03 La Jolla Cancer Research Foundation Carbohydrate specific to chronic myelogenous leukemia granulocytes
US4877599A (en) * 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US4846187A (en) * 1987-12-01 1989-07-11 The Center For Molecular Medicine And Immunology Dual isotope scintigraphic image enhancement
US20030232010A2 (en) * 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
USH735H (en) 1988-03-30 1990-02-06 The United States Of America As Represented By The United States Department Of Energy Lead-203 as a label for radioimaging
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
US5078985A (en) * 1989-08-09 1992-01-07 Rhomed, Incorporated Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction
ES2125854T3 (en) * 1989-08-09 1999-03-16 Rhomed Inc DIRECT RADIO LABELING OF ANTIBODIES AND OTHER PROTEINS WITH TECNETIO OR RENIUM.
CA2331088A1 (en) * 1989-11-03 1991-05-04 Donald L. Morton Urinary tumor associated antigen, antigenic subunits uses and methods of detection
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP3483556B2 (en) * 1992-02-14 2004-01-06 第一サントリーファーマ株式会社 Cell adhesion inhibitory antibody and cell adhesion inhibitor using the same
DE69329112T2 (en) * 1992-05-06 2000-12-14 Immunomedics, Inc. INTRAOPERATIVE, INTRAVASCULAR AND ENDOSCOPIC DETERMINATION AND TREATMENT OF INJURIES AND TUMORS
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US5756825A (en) * 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
GB9314623D0 (en) 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
US5455022A (en) * 1993-09-09 1995-10-03 Associated Universities, Inc. Halogenated sulfidohydroboranes for nuclear medicine and boron neutron capture therapy
DE4337599A1 (en) * 1993-11-01 1995-05-04 Diagnostikforschung Inst Metal-binding cysteine-free peptides for diagnosis and therapy, processes for their preparation and pharmaceutical compositions containing these compounds
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
BR9612619A (en) * 1996-05-15 1999-07-20 Altarex Inc Method and composition for reconforming multiepitopic antigens to initiate an immune response
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US6080384A (en) * 1997-03-25 2000-06-27 American Biogenetic Sciences, Inc. Methods for radionuclide-labeling of biomolecules and kits utilizing the same
GB9725126D0 (en) * 1997-11-27 1998-01-28 Svanborg Catharina Therapeutic agents
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
WO1999059633A1 (en) 1998-05-20 1999-11-25 Immunomedics, Inc. Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
EP1247095B1 (en) 1999-12-06 2008-10-15 Board Of Trustees Of The University Of Illinois High affinity tcr proteins and methods
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
WO2001080884A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
AU2001272017A1 (en) * 2000-06-20 2002-01-02 Immunomedics Inc. Targeted combination immunotherapy of cancer and infectious diseases
WO2002046400A2 (en) * 2000-12-08 2002-06-13 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002078638A2 (en) * 2001-03-30 2002-10-10 University Of Massachusetts Morpholino imaging and therapy
JP4541645B2 (en) 2001-04-12 2010-09-08 インペリアル・イノベイションズ・リミテッド Diagnosis and treatment of type I cancer
US20030003051A1 (en) * 2001-06-11 2003-01-02 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
AU2003223600A1 (en) * 2002-04-11 2003-10-27 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
GB0210464D0 (en) 2002-05-08 2002-06-12 Svanborg Catharina Therapeutic treatment
GB0211658D0 (en) * 2002-05-22 2002-07-03 Svanborg Catharina Novel therapies and methods of screening for therapeutic compounds
EP1507562B1 (en) * 2002-05-29 2010-03-24 Immunomedics, Inc. Compositions for radioimmunotherapy of brain
EP1517684B1 (en) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
EP2036908A3 (en) 2002-07-02 2009-05-13 Health Research, INC. Efficient synthesis of pyropheophorbide a derivates
US20040047858A1 (en) * 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
AU2003270518A1 (en) * 2002-09-11 2004-04-30 The Brigham And Women's Hospital, Inc. Therapeutic anti-bgp(c-cam1) antibodies and uses thereof
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
AU2004213752B2 (en) 2003-01-31 2008-10-23 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
WO2005086612A2 (en) * 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
ES2741574T3 (en) 2004-03-31 2020-02-11 Massachusetts Gen Hospital Method to determine the response of cancer to treatments directed at the epidermal growth factor receptor
EP1735439B1 (en) * 2004-04-12 2011-11-23 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
KR101251157B1 (en) 2005-07-25 2013-04-10 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 B-cell reduction using cd37-specific and cd20-specific binding molecules
EP1933992B1 (en) 2005-08-30 2014-09-24 Advanced Technology Materials, Inc. Boron ion implantation using alternative fluorinated boron precursors, and formation of large boron hydrides for implantation
US20070093708A1 (en) * 2005-10-20 2007-04-26 Benaron David A Ultra-high-specificity device and methods for the screening of in-vivo tumors
EP2674440B1 (en) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
GB0607354D0 (en) * 2006-04-12 2006-05-24 Bioinvent Int Ab Agent, Composition And Method
US7727525B2 (en) 2006-05-11 2010-06-01 City Of Hope Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
EP2041178A2 (en) 2006-06-12 2009-04-01 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
TWI369402B (en) 2006-07-05 2012-08-01 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
JP2008111824A (en) * 2006-09-01 2008-05-15 Nox Technologies Inc NEOPLASM SPECIFIC tNOX ISOFORM AND METHOD THEREFOR
RU2531754C2 (en) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Immunotherapeutic agent combined with cd37, and its combination with bifunctional chemotherapeutic agent
HUE060624T2 (en) 2009-02-13 2023-04-28 Immunomedics Inc Immunoconjugates with an intracellularly-cleavable linkage
KR20180077322A (en) 2009-04-30 2018-07-06 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． Anti ceacam1 antibodies and methods of using same
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US8598022B2 (en) 2009-10-27 2013-12-03 Advanced Technology Materials, Inc. Isotopically-enriched boron-containing compounds, and methods of making and using same
US8138071B2 (en) * 2009-10-27 2012-03-20 Advanced Technology Materials, Inc. Isotopically-enriched boron-containing compounds, and methods of making and using same
US8062965B2 (en) * 2009-10-27 2011-11-22 Advanced Technology Materials, Inc. Isotopically-enriched boron-containing compounds, and methods of making and using same
TWI582836B (en) 2010-02-26 2017-05-11 恩特葛瑞斯股份有限公司 Method and apparatus for enhanced lifetime and performance of ion source in an ion implantation system
US8779383B2 (en) 2010-02-26 2014-07-15 Advanced Technology Materials, Inc. Enriched silicon precursor compositions and apparatus and processes for utilizing same
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
RU2493166C1 (en) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Nanoantibody specifically binding cea protein, method of its usage for detection of this protein
EP2855698A4 (en) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc TARGETING THE PATHWAY FROM GLUTAMINE TO PYRUVATE TO TREAT CANCER ASSOCIATED WITH ONCOGEN KRAS
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
US20150191524A1 (en) 2012-07-27 2015-07-09 The Board Of Trustees Of The University Of Illinoi Engineering t cell receptors
EP2885002A4 (en) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc T-cell redirecting bispecific antibodies for treatment of disease
CN118001422A (en) 2012-12-13 2024-05-10 免疫医疗公司 Dosage of immunoconjugates of antibodies with SN-38 with improved efficacy and reduced toxicity
US9931412B2 (en) 2013-02-08 2018-04-03 The Regents Of The University Of Michigan Targeted theranostics
CN105637616A (en) 2013-08-16 2016-06-01 恩特格里斯公司 Silicon implantation in substrates and provision of silicon precursor compositions therefor
ES2805004T3 (en) 2013-08-19 2021-02-10 Abbott Molecular Inc Nucleotide analogs
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
EP3071594A4 (en) 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
JP6805428B2 (en) 2014-04-27 2021-01-06 フェイムウェイヴ リミテッド Humanized antibody against CEACAM1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
EP3258931B1 (en) 2015-02-17 2020-08-12 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
SI3316885T1 (en) 2015-07-01 2021-09-30 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
AU2018324070B2 (en) 2017-09-01 2023-05-18 East Carolina University Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
US20220249707A1 (en) 2019-05-20 2022-08-11 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211766A (en) * 1972-07-10 1980-07-08 Ab Bonnierforetagen Cancer associated polypeptide antigen compositions
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4160817A (en) * 1976-09-29 1979-07-10 Research Corporation Application of protein-protein interaction as an assay for the detection of cancer
US4174385A (en) * 1976-10-08 1979-11-13 Robert Reid Method of identification of surface proteins of cancer cells, clinical test and method of immunization

Also Published As

Publication number Publication date
US4348376A (en) 1982-09-07

Similar Documents

Publication Publication Date Title
ZA811384B (en) Labeled antibodies and antibody fragments specific to tumor-associated markers, compositions thereof and use thereof in tumor localization an therapy
EP0035265A3 (en) Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
KR880700061A (en) Monoclonal antibodies against antigens related to human cancer tumors
EP0260610A3 (en) Monoclonal antibodies against human tumour necrotic factor (tnf), and their use
EP0597829A4 (en) Novel monoclonal antibody to novel antigen associated with human tumors.
EP0125928A3 (en) Monoclonal antibodies against non small cell lung cancer
GB2182949A (en) Monoclonal antibodies and antigens for human non-small cell lung carcinomas
DE3586216D1 (en) BREAST TUMOR ASSOCIATED ANTIQUE AND MONOCLONAL ANTIBODIES THEREFOR.
DE3070711D1 (en) Valproic acid conjugates and antibodies thereto
EP0131627A4 (en) Specific cea-family antigens, antibodies specific thereto and their methods of use.
ES8704082A1 (en) Tumour therapeutic agent and process for its preparation.
EP0203967A4 (en) Onco-fetal specific monoclonal antibodies, methods of preparation and use.
EP0042428A4 (en) Purified human prostate antigen.
JPS5748914A (en) Tumor inhibiting pharmaceutical composition and use thereof
EP0306680A3 (en) Monoclonal antibodies to anti-thrombin binding substance, and their uses
PT81454A (en) Monoclonal antibodies specific for human squamous lung carcinoma cells their preparation and use
ZA792457B (en) Method and composition for cancer detection in humans
ATE17190T1 (en) AGENT FOR TUMORS LOCALIZATION AND THERAPY WITH LABELED ANTIBODIES AND ANTIBODY FRAGMENTS.
JPS5728088A (en) Olibacine derivative and cancer therapy
AU546797B2 (en) Monoclonal antibodies against tumor antigens and method
JPS54129131A (en) Antiimalignant tumor agent composition
ATE74213T1 (en) MONOCLONAL ANTIBODIES WITH SPECIFIC BINDING TO HUMAN PROSTATE TUMORS ANTIGENS AND METHODS FOR THEIR USE.
GB2112643B (en) Strongly antigenic tumor specific substances and methods for detecting cancer using said substances
IL69998A0 (en) Disopyramide immunogens,antibodies prepared therefrom,labeled conjugates,and the use of such antibodies and labeled conjugates in immunoassays
GB8408987D0 (en) Antibody to human urinary bladder cancer